Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study - Concepedia

Concepedia

Publication | Open Access

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study

DOI Full Paper Access

462

Citations

40

References

2013

Year

Robert Landewé, Jürgen Braun, Atul Deodhar, Maxime Dougados, Walter P. Maksymowych, Philip J. Mease, John D. Reveille, Martín Rudwaleit, Désirée van der Heijde, C. Stach,

Annals of the Rheumatic Diseases

Abstract

CZP rapidly reduced the signs and symptoms of axSpA, with no new safety signals observed compared to the safety profile of CZP in RA. Similar improvements were observed across CZP dosing regimens, and in AS and nr-axSpA patients.

References

	Year	Citations

Page 1